Haematopoietic stem cell transplantation and gene therapy in the fetus: ready for clinical use?
Allogeneic haematopoietic stem cell transplantation in utero has been successfully used for the prenatal treatment of severe combined immunodefiency syndrome. However, this treatment has not been successful in the therapy of other conditions in which the fetus is immunologically competent. The main obstacles to success are lack of competitive advantage of donor versus host stem cells, preventing stable engraftment and graft rejection. Several strategies are being explored to overcome these problems, and some of them have been successful in animal studies. Prenatal gene therapy, using ex-vivo transduced autologous haematopoietic cells or direct gene targeting in utero, is another potential approach in the treatment of immunocompetent fetal recipients. Although this has been shown to be feasible in animal models, safety concerns regarding transduction of fetal germ cells or maternal cells should be addressed in preclinical experiments prior to initiation of clinical trials.
Surbek
D V
DV
Harris Birthright Research Centre for Fetal Medicine, King's College Hospital, London, UK. surbek@hotmail.com
Holzgreve
W
W
Nicolaides
K H
KH
D000818:Animals; D005260:Female; D005315:Fetal Diseases / Q000628:therapy*; D018390:Gene Targeting; D015316:Genetic Therapy; D006084:Graft Rejection; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells; D006801:Humans; D011247:Pregnancy